Stockholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2026

A summary of the Company’s stock option activity for the three months ended March 31, 2026 and related information is as follows (in thousands, except per share data):


	Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value
Outstanding at December 31, 2025	12,914	$	2.73	4.4	$	1,461
Options granted	—	$	—
Options exercised	(698)	$	1.55
Options forfeited or expired	(220)	$	2.93
Outstanding at March 31, 2026	11,996	$	2.80	4.3	$	12
Exercisable at March 31, 2026	11,996	$	2.80	4.3	$	12
Vested or expected to vest at March 31, 2026	11,996	$	2.80	4.3	$	12

Schedule of Restricted Stock Unit Activity

A summary of the Company’s RSU activity for the three months ended March 31, 2026 and related information is as follows (in thousands, except per share data):


	Number of Shares	Weighted Average Grant Date Fair Value
Unvested at December 31, 2025	47,101	$	1.95
RSUs granted	33,863	$	1.73
RSUs vested	(5,937)	$	2.10
RSUs forfeited	(1,719)	$	1.84
Unvested at March 31, 2026	73,308	$	1.84

Schedule of Assumptions Used to Calculate Fair Value

The following assumptions were used to calculate the fair value of market-based PSUs made during the following periods:


	Three Months Ended March 31,
	2026	2025
Expected volatility	63.9% - 65.4%	66.5%
Expected term (in years)	3.8 - 3.9	4.9
Risk-free interest rate	3.6% - 3.9%	4.1%
Expected dividend yield	—	—

Schedule of Stock-based Compensation Expense

The Company recorded stock-based compensation expense in the condensed consolidated statements of operations as follows (in thousands):


	Three Months Ended March 31,
	2026		2025
Cost of revenue	$	622	$	745
Research and development	8,363		9,188
Sales and marketing	1,935		2,472
General and administrative	3,842		4,686
Total	$	14,762	$	17,091